General Information of Drug (ID: DM0Q7NO)

Drug Name
AMG 176 Drug Info
Synonyms
JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [1]
Multiple myeloma 2A83 Phase 1 [2]
Cross-matching ID
PubChem CID
118910268
CAS Number
CAS 1883727-34-1
TTD Drug ID
DM0Q7NO

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) TTL53M6 MCL1_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DTT MCL1 7.695 6.404 5.954 6.82
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DTT MCL1 1.06E-04 1.29 2.97
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03797261) A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)